A comparison of immunosuppressive therapies for the treatment of diffuse cutaneous systemic sclerosis found “robust” support for mycophenolate mofetil as the first-line standard of care, according to data published in ACR Open Rheumatology.
The drug was superior to methotrexate, steroids and other immunosuppressive therapies for skin and lung outcomes, and was particularly advantageous for patients with early disease or interstitial lung disease.
“There’s very little known about what drugs are effective in scleroderma,” Robert F. Spiera, MD, director of the
